Image source: Getty Images.
Continue Reading Below
Shares of Botox maker Allergan (NYSE: AGN) shed nearly 14% of their value in October, according to data fromS&P Global Market Intelligence.
The silver lining is that Allergan's shares appear to have slumped simply as a result of the growing fear of a Hillary Clinton presidency that may spark a legal and political battle over drug pricing in the United States. Allergan, after all, maintained radio silence for most of the month, and many of its peers performed equally poorly as well, on little to no news.
Continue Reading Below
This arguably irrational fear that's been slamming biopharmas like Allergan lately is perhaps overblown at this point. Allergan's shares are currently trading close to their 52-week lows -- even though the drugmaker has markedly improved its balance sheet, continues to post strong growth within its branded pharma segment, and has an outstanding shareholder rewards program in place.
Allergan's fate does not depend solely on the outcome of the election come Tuesday, even though the market seems to think otherwise. The fact of the matter is that Allergan sports a diverse portfolio of growth products, many of which are just now hitting their stride commercially.
Take for instance Allergan's all-important eye care franchise that sports products like Restasis,Lumigan, andOzurdex. In the third quarter, the company reported that total eye care product sales rose by an astounding 46.5% in the first nine months of 2016 compared to the same period in 2015. That's outstanding growth for a large cap pharma in any environment -- yet the market has turned a blind eye purely as a result of the ongoing political turmoil.
Of course, there is the offhand chance that Clinton, if she were to win, would attempt to follow through on her campaign rhetoric regarding drug prices. Even so, this remote possibility appears to be more than baked into Allergan's price at this point, implying that now may indeed be a good time to start buying this top pharma stock.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
George Budwell owns shares of Allergan. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.